126 related articles for article (PubMed ID: 36395809)
1. Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial.
Lourenco RA; Khoo T; Crothers A; Haas M; Montgomery R; Ball D; Bressel M; Siva S
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):968-976. PubMed ID: 36395809
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care.
Raymakers AJN; Cameron D; Tyldesley S; Regier DA
Curr Oncol; 2021 May; 28(3):1857-1866. PubMed ID: 34068400
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer.
Kumar A; Straka C; Courtney PT; Vitzthum L; Riviere P; Murphy JD
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1185-1194. PubMed ID: 33002541
[TBL] [Abstract][Full Text] [Related]
4. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
Siva S; Bressel M; Mai T; Le H; Vinod S; de Silva H; Macdonald S; Skala M; Hardcastle N; Rezo A; Pryor D; Gill S; Higgs B; Wagenfuehr K; Montgomery R; Awad R; Chesson B; Eade T; Wong W; Sasso G; De Abreu Lourenco R; Kron T; Ball D; Neeson P;
JAMA Oncol; 2021 Oct; 7(10):1476-1485. PubMed ID: 34455431
[TBL] [Abstract][Full Text] [Related]
5. Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial.
Qu XM; Chen Y; Zaric GS; Senan S; Olson RA; Harrow S; John-Baptiste A; Gaede S; Mulroy LA; Schellenberg D; Senthi S; Swaminath A; Kopek N; Liu M; Warner A; Rodrigues GB; Palma DA; Louie AV
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1176-1184. PubMed ID: 33309977
[TBL] [Abstract][Full Text] [Related]
6. Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.
Olson R; Abraham H; Leclerc C; Benny A; Baker S; Matthews Q; Chng N; Bergman A; Mou B; Dunne EM; Schellenberg D; Jiang W; Chan E; Atrchian S; Lefresne S; Carolan H; Valev B; Tyldesley S; Bang A; Berrang T; Clark H; Hsu F; Louie AV; Warner A; Palma DA; Howell D; Barry A; Dawson L; Grendarova P; Walker D; Sinha R; Tsai J; Bahig H; Thibault I; Koul R; Senthi S; Phillips I; Grose D; Kelly P; Armstrong J; McDermott R; Johnstone C; Vasan S; Aherne N; Harrow S; Liu M
BMC Cancer; 2024 Feb; 24(1):171. PubMed ID: 38310262
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease.
Mehrens D; Unterrainer M; Corradini S; Niyazi M; Manapov F; Westphalen CB; Froelich MF; Wildgruber M; Seidensticker M; Ricke J; Rübenthaler J; Kunz WG
Front Oncol; 2021; 11():667993. PubMed ID: 34211842
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma.
Jin H; Chalkidou A; Hawkins M; Summers J; Eddy S; Peacock JL; Coker B; Kartha MR; Good J; Pennington M;
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):e143-e154. PubMed ID: 32951952
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases.
Siva S; Sakyanun P; Mai T; Wong W; Lim A; Ludbrook J; Bettington C; Rezo A; Pryor D; Hardcastle N; Kron T; Higgs B; Le H; Skala M; Gill S; Eade T; Awad R; Sasso G; Vinod S; Montgomery R; Ball D; Bressel M
J Clin Oncol; 2023 Jul; 41(19):3493-3498. PubMed ID: 37179526
[No Abstract] [Full Text] [Related]
10. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases.
Verma V; Yegya-Raman N; Sprave T; Han G; Kantarjian HM; Welsh JW; Chang JY; Lin SH
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):977-988. PubMed ID: 35675852
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases.
Lester-Coll NH; Dosoretz AP; Magnuson WJ; Laurans MS; Chiang VL; Yu JB
J Neurosurg; 2016 Dec; 125(Suppl 1):18-25. PubMed ID: 27903191
[TBL] [Abstract][Full Text] [Related]
14. Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada.
Louie AV; Rodrigues GB; Palma DA; Senan S
Oncologist; 2014 Aug; 19(8):880-5. PubMed ID: 24951606
[TBL] [Abstract][Full Text] [Related]
15. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
17. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
Shaw L; Rodgers H; Price C; van Wijck F; Shackley P; Steen N; Barnes M; Ford G; Graham L;
Health Technol Assess; 2010 May; 14(26):1-113, iii-iv. PubMed ID: 20515600
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases.
Lester-Coll NH; Rutter CE; Bledsoe TJ; Goldberg SB; Decker RH; Yu JB
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):663-72. PubMed ID: 27055395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
